Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01408953 · ClinicalTrials.gov registry record · Phase 2
Therapeutic Study of Bevacizumab Injection Directly Inside the Keloid Tissue
A Phase 2 study, sponsored by Tirgan, Michael H., M.D..
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01408953: Clinical Trial Phase 2 study, sponsored by Tirgan, Michael H., M.D..
NCT01408953 is a Phase 2 study that was terminated before completion, run by Tirgan, Michael H., M.D.. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01408953, a Phase 2 study, was terminated before completion, sponsored by Tirgan, Michael H., M.D..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Keloid is chronic skin conditions that results in formation of tumor like growths on the skin. Despite its benign nature, keloid can cause severe aesthetic and, in some cases, functional problem which negatively impacts person's quality of life. Keloids do not regress on their own and results of most available treatments such as surgery, injecting keloids with steroids, chemotherapy injections, or even radiation therapy, have mostly proven disappointing. Some laboratory studies have shown that there is excessive amount of a protein called "vascular endothelial growth factor (VEGF)" in keloid tissue. This may play role in the formation and evolution of keloid. Bevacizumab is a drug that works by targeting vascular endothelial growth factor (VEGF) which helps new blood vessels form. Without new blood vessels, the growth of the keloid may be slowed Based on presence of excess amount of VEGF in keloid tissue, we hypothesize that bevacizumab will be effective in treatment of keloids. This exploratory clinical trial is to confirm or reject this hypothesis.
Primary Outcome
The primary objective of this trial is to demonstrate the efficacy of bevacizumab in patients with non-pedunculated keloids. Patients will be followed for one year since their last bevacizumab to assess post-therapy duration of response as well as the rate of recurrence.
Interventions
- BIOLOGICAL bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-02 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Why NCT01408953 stopped before completion
NCT01408953 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which bevacizumab is the first listed.
NCT01408953 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01408953 about?
NCT01408953 is a clinical study titled "Therapeutic Study of Bevacizumab Injection Directly Inside the Keloid Tissue". Keloid is chronic skin conditions that results in formation of tumor like growths on the skin. Despite its benign nature, keloid can cause severe aesthetic and, in some cases, functional problem which negatively impacts person's quality of life. Keloids do not regress on their own and results of mo...
What is the current status of trial NCT01408953?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2012-02. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01408953?
The interventions under investigation include: bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01408953?
This trial is sponsored by Tirgan, Michael H., M.D., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01408953's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia